Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).
Approximately 50%-95% of prostate cancer patients undergoing radiation therapy (RT) develop
symptomatic urinary problems .These symptoms can significantly diminish a patient's quality
of life during and shortly after therapy. Alpha1-blockers, such as Rapaflo, act to decrease
resistance to urinary flow.
This multi-institutional phase III trial is designed to compare standard of care versus
preventive treatment with Rapaflo for prostate cancer patients, regardless of risk group,
whose treatment consists of radical radiation therapy. We plan to recruit 188 patients
across Quebec who will be randomized into two arms: rapaflo prescribed at start of radiation
therapy or if/when symptoms appear.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society